Skip to main content
PTC THERAPEUTICS, INC. logo

PTC THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · PTCT ISIN · US69366J2006 LEI · 549300UJLWOIWFDGB318 US Manufacturing
Open in API
Filings indexed 1,161 across all filing types
Latest filing 2020-08-05 Earnings Release
Country US United States of America
Listing US PTCT

About PTC THERAPEUTICS, INC.

https://www.ptcbio.com/

PTC Therapeutics, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for children and adults with rare and serious diseases. The company focuses on conditions with high unmet medical needs, leveraging its expertise across multiple scientific platforms. These platforms include RNA biology, with a focus on splicing modification to control protein production, and targeting inflammation and ferroptosis pathways for central nervous system diseases. PTC has brought several pioneering treatments to market, including the first approved therapy for Duchenne muscular dystrophy, the first gene therapy administered directly into the brain, and the first small molecule splicing modifier. The company maintains a diversified pipeline of innovative therapies.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text specifically mentions the announcement of financial results for the quarter ended June 30, 2020, and includes a press release as an exhibit. It also references a conference call to discuss these results. The document does not contain the full financial statements or detailed financial analysis itself but rather announces the results and provides a press release. The length is 4271 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results.
2020-08-05 English
8-K
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement, specifically a Royalty Purchase Agreement involving a significant financing transaction ($650 million cash consideration). It also includes a press release about the closing of this agreement. There are no financial statements or detailed financial performance data included, only a description of the transaction and related covenants. This fits the category of Capital/Financing Update, as it reports on a financing activity and capital structure change. The document length (11,550 characters) is sufficient to contain substantive information, not just a brief announcement. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-07-20 English
FORM 4
Director's Dealing
2020-07-17 English
Regulatory Filings 2020
Regulatory Filings
2020-07-15 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-10 English
FORM 4
Director's Dealing
2020-07-09 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.